• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases.

作者信息

Tapia-Sosa R, Hernández-Cabral F, Gabutti A, Páez-Zayas V M, García-Juárez I

机构信息

Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Departamento de Imagenología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

出版信息

Rev Gastroenterol Mex (Engl Ed). 2021 Apr-Jun;86(2):197-199. doi: 10.1016/j.rgmx.2020.04.008. Epub 2020 Nov 11.

DOI:10.1016/j.rgmx.2020.04.008
PMID:33187768
Abstract
摘要

相似文献

1
Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases.
Rev Gastroenterol Mex (Engl Ed). 2021 Apr-Jun;86(2):197-199. doi: 10.1016/j.rgmx.2020.04.008. Epub 2020 Nov 11.
2
End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.故事的结局：直接抗病毒药物与肝细胞癌复发无关。
Gut. 2022 Mar;71(3):454-456. doi: 10.1136/gutjnl-2021-324288. Epub 2021 Mar 30.
3
No differences in the risk of hepatocellular carcinoma from using direct-acting antiviral agents or interferon in patients with chronic hepatitis C: A meta-analysis.
Clin Res Hepatol Gastroenterol. 2022 Dec;46(10):102001. doi: 10.1016/j.clinre.2022.102001. Epub 2022 Aug 12.
4
The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
J Formos Med Assoc. 2021 Apr;120(4):1160. doi: 10.1016/j.jfma.2020.11.012. Epub 2020 Dec 5.
5
[Impression of direct-acting antiviral agents in the treatment of recurrent hepatocellular carcinoma related to chronic hepatitis C].
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):179-183. doi: 10.3760/cma.j.issn.1007-3418.2018.03.005.
6
Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma".对致编辑信《直接抗病毒药物清除丙型肝炎病毒后细胞因子变化对肝细胞癌风险的影响》的回复
J Formos Med Assoc. 2021 Apr;120(4):1161-1164. doi: 10.1016/j.jfma.2020.12.016. Epub 2020 Dec 24.
7
[Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].[丙型肝炎病毒经直接抗病毒药物治愈后发生肝细胞癌的风险：下一个挑战]
Med Sci (Paris). 2018 May;34(5):391-394. doi: 10.1051/medsci/20183405007. Epub 2018 Jun 13.
8
Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals.在接受直接抗病毒药物治疗期间被诊断为肝细胞癌的丙型肝炎病毒感染患者中出现的意外病毒复发。
Hepatology. 2017 Sep;66(3):992-994. doi: 10.1002/hep.29181. Epub 2017 Jul 18.
9
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.全口服直接抗病毒方案对丙型肝炎病毒基因1型相关慢性肝病患者肝细胞癌发生率的影响
Oncology. 2017;93(2):92-98. doi: 10.1159/000470910. Epub 2017 Apr 28.
10
Surveillance for hepatocellular carcinoma after hepatitis C virus eradication.
Minerva Med. 2022 Jun;113(3):569-570. doi: 10.23736/S0026-4806.20.06496-4. Epub 2020 Mar 12.

引用本文的文献

1
Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches.肝细胞癌、丙型肝炎病毒感染与 miRNA 作用：新治疗方法的展望。
World J Gastroenterol. 2022 Jun 14;28(22):2417-2428. doi: 10.3748/wjg.v28.i22.2417.